• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [17382 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: noninvasive fetal RhD genotyping using maternal plasma]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: artificial intelligence-assisted diabetic retinopathy tele-screening]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2021     NIHR Health Technology Assessment programme Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation
2021     Norwegian Institute of Public Health (NIPH) Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - health economic evaluation
2021     Norwegian Institute of Public Health (NIPH) Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bronchial thermoplasty in severe asthma]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for treatment of symptomatic uterine myomas]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Horizon Scanning Technologies]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic navigation bronchocopy with or without assisted robotics: use in lung nodules diagnosing process. Horizon Scanning Technologies]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic navigation bronchoscopy: use in lung nodules placement markers and resection process. Horizon Scanning Technologies]
2021     NIHR Health Technology Assessment programme Cognitive–behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis
2021     NIHR Health Technology Assessment programme Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study
2021     NIHR Health Services and Delivery Research programme Respite care and short breaks for young adults aged 18–40 with complex health-care needs: mixed-methods systematic review and conceptual framework development
2021     Norwegian Institute of Public Health (NIPH) Surgery for carpal tunnel syndrome: a health technology assessment
2021     NIHR Health Technology Assessment programme Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021     Norwegian Institute of Public Health (NIPH) Evaluation of tests for FLT3 mutations in acute myeloid leukaemia (AML)
2021     Norwegian Institute of Public Health (NIPH) Subacromial decompression surgery for impingement syndrome: rapid health technology assessment
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) Clinical Practice Guideline on palliative care (Update)
2021     Ontario Health Blue light (fluorescence) cystoscopy with hexaminolevulinate hydrochloride in non-muscle bladder cancer
2021     Ontario Health Internet-delivered cognitive behavioral therapy for post-traumatic stress disorder and acute stress disorder
2021     Ontario Health iStent for people with open angle glaucoma
2021     Ontario Health DPYD genotyping in patients with cancer treated with fluoropyrimidines
2021     Ontario Health Multi-gene pharmacogenomic testing to guide medication selection for people with major depression
2021     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2021     Ontario Health Nonthermal minimally invasive treatments for varicose veins
2021     Ontario Health Prostatic artery embolization for benign prostatic hyperplasia
2021     Ontario Health Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers
2021     Ontario Health Repetitive transcranial magnetic stimulation (rTMS) for people with treatment-resistant depression
2021     Ontario Health Pigmented lesion assay for suspected melanoma lesions
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of the SpaceOAR hydrogel rectal spacer during prostate radiotherapy]
2021     Ontario Health Use of B-type natriuretic peptide and N Terminal-pro B-type natriuretic peptide as diagnostic tests in people with suspected heart failure
2021     Ontario Health Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2021     Scottish Medicines Consortium (SMC) Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021     Scottish Medicines Consortium (SMC) Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021     Scottish Medicines Consortium (SMC) Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2020     Technology Assessment at SickKids (TASK) Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-CoV-2 in the management of the pandemic
2020     Norwegian Institute of Public Health (NIPH) Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020     Norwegian Institute of Public Health (NIPH) Intracoronary lithotripsy for the treatment of coronary artery disease: a health technology assessment
2020     Norwegian Institute of Public Health (NIPH) Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ infections caused by chlamydia trachomatis and neisseria gonorrhoeae]
2020     NIHR Health Technology Assessment programme Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
2020     NIHR Health Technology Assessment programme Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
2020     Austrian Institute for Health Technology Assessment (AIHTA) Update PET/PET-CT evidence for need based planning in the area of oncology
2020     NIHR Health Technology Assessment programme Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation
2020     NIHR Health Technology Assessment programme Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation
2020     Austrian Institute for Health Technology Assessment (AIHTA) Proton and carbon ion therapy - an update on indications
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2020     NIHR Health Technology Assessment programme Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation
2020     NIHR Health Technology Assessment programme Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob disease: a cost-effective modelling review
2020     Swiss Federal Office of Public Health (FOPH) Olmesartan Mono- and Combination Therapies in Patients with Essential Hypertension
2020     Swiss Federal Office of Public Health (FOPH) Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitors
2020     Swiss Federal Office of Public Health (FOPH) Chondroitin Sulfate in Osteoarthritis
2020     Swiss Federal Office of Public Health (FOPH) Iron Therapy for Iron Deficiency without Anemia
2020     Health Technology Wales (HTW) Autologous haematopoietic stem cell transplantation for previously treated, relapsing-remitting multiple sclerosis
2020     Health Technology Wales (HTW) Pre-operative cardiopulmonary exercise testing for people in whom major abdominal surgery is planned
2020     Health Technology Wales (HTW) Rapid antigen detecting tests for diagnosing group A streptococcal infections in the community pharmacy setting
2020     Health Technology Wales (HTW) Transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis who are at intermediate surgical risk
2020     Health Technology Wales (HTW) Point of care haemolysis detection in blood samples that may be deemed unfit for laboratory analysis
2020     NIHR Health Technology Assessment programme Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of the left ventricular assist device (LVAD) as destination therapy in paediatric patients]
2020     NIHR Health Services and Delivery Research programme The effects of interoperable information technology networks on patient safety: a realist synthesis
2020     European Network for Health Technology Assessment (EUnetHTA) Rolling Collaborative Review COVID-19 - Lopinavir + Ritonavir
2020     NIHR Health Services and Delivery Research programme Social norms interventions to change clinical behaviour in health workers: a systematic review and meta-analysis
2020     Belgian Health Care Knowledge Centre (KCE) Polyvalent immunoglobulins – Part 2: use in Belgium
2020     Norwegian Institute of Public Health (NIPH) [Intermittent pneumatic compression for preventing deep vein thrombosis in acute stroke, a health technology assessment]
2020     Norwegian Institute of Public Health (NIPH) [Effectiveness of microwave thermotherapy (TUMT) compared to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia]
2020     NIHR Health Technology Assessment programme Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2020     National Committee for Technology Incorporation (CONITEC) [Dolutegravir for the treatment of pregnant women living with HIV]
2020     National Committee for Technology Incorporation (CONITEC) [Baricitinib (Olumiant) for patients with moderate to severe active rheumatoid arthritis]
2020     National Committee for Technology Incorporation (CONITEC) [Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2020     National Committee for Technology Incorporation (CONITEC) [Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2020     National Committee for Technology Incorporation (CONITEC) [Photodynamic therapy for non-melanoma skin cancer]
2020     National Committee for Technology Incorporation (CONITEC) [Newborn screening for congenital toxoplasmosis]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020     National Committee for Technology Incorporation (CONITEC) [Riociguat for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Orlistat for weight loss in overweight or obese patients]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Sibutramine for the treatment of obese patients]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2020     National Committee for Technology Incorporation (CONITEC) [Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2020     NIHR Health Technology Assessment programme Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2020     National Committee for Technology Incorporation (CONITEC) [Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020     National Committee for Technology Incorporation (CONITEC) [Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code] Book V
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Givosiran (acute hepatic porphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]